Skip to main content

Peer Review reports

From: ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Original Submission
9 Jan 2022 Submitted Original manuscript
23 Jan 2022 Reviewed Reviewer Report
1 Feb 2022 Reviewed Reviewer Report - Ziming Li
28 Feb 2022 Author responded Author comments - Wei Nie
Resubmission - Version 2
28 Feb 2022 Submitted Manuscript version 2
2 Mar 2022 Reviewed Reviewer Report
19 Mar 2022 Reviewed Reviewer Report - Ziming Li
25 Mar 2022 Author responded Author comments - Wei Nie
Resubmission - Version 3
25 Mar 2022 Submitted Manuscript version 3
Publishing
29 Mar 2022 Editorially accepted
5 May 2022 Article published 10.1186/s12916-022-02360-x

You can find further information about peer review here.

Back to article page